Pharmaceutical Research & Development

Our Drug Pipeline

Our drug research and development pipeline

Our product pipeline reflects our commitment to developing innovative products that help diagnose or treat gastrointestinal disorders. Salix focuses on innovative gastrointestinal products and investigating currently marketed products for new indications. This page features information on the compounds currently in our pipeline. Information on this page is current as of 11/25/2014.


Program Indication Clinical Phases
PHASE 2  PHASE 3
NDA/BLA
Under Review
Methylnaltrexone Bromide
MDP (Multi-Dose Pen)
Opioid induced constipation (OIC) in advanced illness  
Methylnaltrexone Bromide
(Oral Formulation)
OIC in chronic non-cancer pain  
Rifaximin
for the treatment of IBS-D*
Irritable bowel syndrome with diarrhea
Rifaximin DR
(Delayed Release)
Crohn's disease
 
Rifaximin SSD
(Soluble Solid Dispersion)
Prevention of complications with early decompensated liver cirrhosis  
Investigational Bowel Purgative Bowel prep for preparation of colonoscopy and other abdominal procedures In development
SAN-300 Rheumatoid Arthritis  

2014 Drug Approvals and press release date; Budesonide Foam (08Oct2014), Methylnaltrexone Bromide SC Injection (29Sept2014), Ruconest (17Jul2014)
*The resubmission of sNDA for IBS-D is considered a class 2 response to the FDA's March 7, 2011 action letter and has been assigned a user fee goal date of February 28, 2015.

SAL-US-0003 v1

Check out our latest Press Releases and News